Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 5:35 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 121–144 of 8,137 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Period 1 Clear all

Conditions: Pneumonia
Interventions: CP-70,429 and PF-03709270; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 29 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2010
U.S. locations: 1
States / cities: Indianapolis, Indiana

Conditions: Autism Spectrum Disorder
Interventions: Sertraline Liquid Placebo, Sertraline; Drug
Lead sponsor: Randi J. Hagerman, MD; Other
Eligibility: 24 Months to 72 Months
Enrollment: 58 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 1
States / cities: Sacramento, California

Conditions: Lower Extremity Problem
Interventions: Education Program on Injury Prevention, Individualized Feedback + Education Program on Injury Prevention; Behavioral
Lead sponsor: San Diego State University; Other
Eligibility: 18 Years to 25 Years · Female only
Enrollment: 18 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023
U.S. locations: 1
States / cities: San Diego, California

Conditions: Healthy
Interventions: ALXN1840, Omeprazole; Drug
Lead sponsor: Alexion Pharmaceuticals, Inc.; Industry
Eligibility: 19 Years to 55 Years
Enrollment: 18 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014
U.S. locations: 1
States / cities: Lincoln, Nebraska

Conditions: Multiple Myeloma
Interventions: Bortezomib; Drug
Lead sponsor: Boston VA Research Institute, Inc.; Other
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2015
U.S. locations: 11
States / cities: Little Rock, Arkansas • Los Angeles, California • San Francisco, California + 8 more

Conditions: Diffuse Large B-Cell Lymphoma, High Grade B-Cell Lymphoma
Interventions: Venetoclax, Rituximab, Etoposide, Vincristine Sulfate, Cyclophosphamide, Prednisone, Doxorubicin Hydrochloride; Drug
Lead sponsor: Weill Medical College of Cornell University; Other
Eligibility: 18 Years to 80 Years
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2021
U.S. locations: 6
States / cities: Boston, Massachusetts • St Louis, Missouri • New York, New York + 3 more

Conditions: Glaucoma, Open-Angle, Ocular Hypertension
Interventions: Bimatoprost SR, Sham: Applicator Without Needle, Active Comparator: Timolol 0.5%, Timolol Vehicle (placebo); Drug · Other
Lead sponsor: Allergan; Industry
Eligibility: 18 Years and older
Enrollment: 528 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2020
U.S. locations: 51
States / cities: Dothan, Alabama • Chandler, Arizona • Fayetteville, Arkansas + 47 more

Conditions: Acute Myeloid Leukemia, Myelodysplastic Syndromes
Interventions: Interferon gamma-1b, Donor Leukocyte Infusion (DLI); Drug · Biological
Lead sponsor: Sawa Ito, MD; Other
Eligibility: 18 Years and older
Enrollment: 57 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2029
U.S. locations: 3
States / cities: St Louis, Missouri • Pittsburgh, Pennsylvania • Seattle, Washington

Conditions: Stroke, Traumatic Brain Injury, Multiple Sclerosis
Interventions: Functional Electrical Stimulation, Normal care; Device
Lead sponsor: Casa Colina Hospital and Centers for Healthcare; Other
Eligibility: 18 Years to 80 Years
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Pomona, California

Conditions: Melanoma
Interventions: A combination of intratumoral IFN-gamma plus systemic vaccination with MELITAC 12.1; Biological
Lead sponsor: Craig L Slingluff, Jr; Other
Eligibility: 18 Years and older
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2009
U.S. locations: 1
States / cities: Charlottesville, Virginia

Conditions: Lung Cancer, Survivor
Interventions: interview and physical activity, interview and wait list; Behavioral
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 21 Years and older
Enrollment: 52 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2023
U.S. locations: 1
States / cities: New York, New York

Conditions: Age-related Macular Degeneration
Interventions: Subcutaneous elamipretide through the elamipretide delivery system, Subcutaneos placebo through the elamipretide delivery system; Combination Product
Lead sponsor: Stealth BioTherapeutics Inc.; Industry
Eligibility: 55 Years and older
Enrollment: 176 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 37
States / cities: Peoria, Arizona • Phoenix, Arizona • Scottsdale, Arizona + 30 more

Conditions: Visual Acuity
Interventions: Acuvue Oasys 1 Day for Astigmatism, TRA100/TRA200 series toric contact lens with HEVL-blocking chromophore; Device
Lead sponsor: Johnson & Johnson Vision Care, Inc.; Industry
Eligibility: 18 Years to 39 Years
Enrollment: 188 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023
U.S. locations: 10
States / cities: Jacksonville, Florida • Longwood, Florida • Maitland, Florida + 7 more

Conditions: Healthy Volunteers
Interventions: TAK-788, Placebo; Drug
Lead sponsor: Millennium Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 69 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Dysphagia
Interventions: Pharyngocise; Behavioral
Lead sponsor: University of Florida; Other
Eligibility: 21 Years to 90 Years
Enrollment: 130 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2011
U.S. locations: 1
States / cities: Gainesville, Florida

Conditions: Well-Being, Psychological, Work Injury, Musculoskeletal Pain, High Frequency Heart Rate Variability, Burnout, Mindfulness, Self-Compassion, Acceptance and Commitment Therapy, Heart Rate Variability
Interventions: Eastern Principles Acceptance and Commitment Therapy for Nurses and Nursing Aids (EPACT NNA), Acceptance and Commitment Therapy for Nurses and Nursing Aids (ACT NNA); Behavioral
Lead sponsor: Bowling Green State University; Other
Eligibility: 18 Years and older
Enrollment: 255 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 1
States / cities: Bowling Green, Ohio

Conditions: End Stage Renal Disease on Dialysis, Adult
Interventions: Intravenous fosmanogepix; Drug
Lead sponsor: Basilea Pharmaceutica; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2027
U.S. locations: 2
States / cities: Orlando, Florida • Tampa, Florida

Conditions: Post-stroke Spasticity of the Lower Limb
Interventions: IncobotulinumtoxinA (400 Units), Placebo Comparator; Drug
Lead sponsor: Merz Pharmaceuticals GmbH; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 290 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2015
U.S. locations: 12
States / cities: Downey, California • Long Beach, California • Fairfield, Connecticut + 9 more

Conditions: Human Immunodeficiency Virus Type 1 (HIV-1)
Interventions: Atazanavir, Cobicistat, Atazanavir/Cobicistat FDC; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years to 49 Years
Enrollment: 64 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Attention Deficit Hyperactivity Disorder (ADHD)
Interventions: LDX 30 mg, LDX 50 mg, LDX 70 mg, Placebo; Drug
Lead sponsor: Shire; Industry
Eligibility: 13 Years to 17 Years
Enrollment: 314 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 45
States / cities: Little Rock, Arkansas • El Centro, California • Rolling Hills Estates, California + 40 more

Conditions: Asthma
Interventions: FS MDPI, Fp MDPI, Placebo MDPI, albuterol/salbutamol, Beclomethasone dipropionate; Drug
Lead sponsor: Teva Branded Pharmaceutical Products R&D, Inc.; Industry
Eligibility: 12 Years and older
Enrollment: 787 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 76
States / cities: Birmingham, Alabama • Glendale, Arizona • Cypress, California + 64 more

Conditions: Psoriasis
Interventions: Risankizumab, Apremilast; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years and older
Enrollment: 352 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 26
States / cities: Birmingham, Alabama • Glendale, Arizona • Phoenix, Arizona + 22 more

Conditions: Bipolar Disorder
Interventions: Ketone Ester Beverage, Low Glycemic Index Diet; Dietary Supplement · Behavioral
Lead sponsor: University of Michigan; Other
Eligibility: 18 Years and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 2
States / cities: Ann Arbor, Michigan

Conditions: Healthy Adults
Interventions: Prifetrastat; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026
U.S. locations: 1
States / cities: New Haven, Connecticut

Search by objective public record fields.

A Study To Investigate The Pharmacokinetics, Safety And Tolerability Of An Intravenous And Oral Form Of A Compound In Subjects With Varying Degrees Of Renal Impairment And Normal Renal Function

A Trial of Sertraline in Young Children With Autism Spectrum Disorder

Injury Prevention for Female Lacrosse Athletes

A Study of ALXN1840 (Non-coated) Administered With And Without Omeprazole In Healthy Adults

Safety and Efficacy Study of Single Weekly Bortezomib in Newly Diagnosed Multiple Myeloma

Study of Venetoclax Plus DA-EPOCH-R for the Treatment of Aggressive B-Cell Lymphomas

Efficacy and Safety of Bimatoprost Sustained-Release (SR) in Patients With Open-Angle Glaucoma or Ocular Hypertension

Interferon-γ (IFN-γ) With Donor Leukocyte Infusion to Treat Relapsed Acute Myeloid Leukemia and Myelodysplastic Syndromes Post Allogeneic Hematopoietic Stem Cell Transplantation

Comparison of Gait Metrics in Patients With Stroke, Traumatic Brain Injury, and Multiple Sclerosis

Evaluating the Safety and the Biological Effects of Intratumoral Interferon Gamma and a Peptide-Based Vaccine in Patients With Melanoma

Physical Activity Intervention for Lung Cancer Survivors

ReCLAIM-2 Study to Evaluate Safety,Efficacy & Pharmacokinetics of Elamipretide in Subjects With AMD With Non-central GA

Design Validation of Toric Contact Lenses in Senofilcon A With a Blue-Blocking Chromophore

A Study to Evaluate the Pharmacokinetics (PK), Safety and Tolerability of TAK-788 Followed by Evaluation of the Effects of a Low-Fat Meal on TAK-788 PK and Evaluation of Relative Bioavailability of TAK-788 Capsules in Healthy Participants

Pharyngocise Dose Response Study

Eastern Principles Acceptance and Commitment Therapy For Injury Prevention Among Nurses and Nursing Aides

A Study to Test the Safety of the Study Drug Fosmanogepix and How the Body Handles It in Adults With Severe Kidney Failure on Dialysis

Efficacy and Safety Study of Botulinum Toxin Type A Against Placebo to Treat Spasticity in the Leg After a Stroke

Bioequivalence Study of Individual Atazanavir and Cobicistat Compared With Atazanavir in Fixed-dose Combination With Cobicistat

Efficacy and Safety of Lisdexamfetamine Dimesylate (LDX) in Adolescents With Attention-Deficit/Hyperactivity Disorder (ADHD)

Study of Fluticasone Propionate MDPI Compared With Fluticasone/Salmeterol MDPI in Adolescent and Adult Patients With Persistent Asthma

Study of Subcutaneous Risankizumab Injection Compared to Oral Apremilast Tablets to Assess Change in Disease Activity And Adverse Events in Adult Participants With Moderate Plaque Psoriasis Who Are Candidates for Systemic Therapy

Brain Small Chain Fatty Acid Metabolism in Bipolar Disorder: Ketones

A Study to Learn About How Food Affects the Uptake of Study Medicine Prifetrastat Into the Blood in Healthy Adults